CY1121819T1 - Φαρμακευτικα παρασκευασματα ανθρωπινων rpe κυτταρων και χρησεις αυτων - Google Patents

Φαρμακευτικα παρασκευασματα ανθρωπινων rpe κυτταρων και χρησεις αυτων

Info

Publication number
CY1121819T1
CY1121819T1 CY20191100720T CY191100720T CY1121819T1 CY 1121819 T1 CY1121819 T1 CY 1121819T1 CY 20191100720 T CY20191100720 T CY 20191100720T CY 191100720 T CY191100720 T CY 191100720T CY 1121819 T1 CY1121819 T1 CY 1121819T1
Authority
CY
Cyprus
Prior art keywords
cells
hesc
patients
rpe
signs
Prior art date
Application number
CY20191100720T
Other languages
Greek (el)
English (en)
Inventor
Roger GAY
Irina Klimanskaya
Robert Lanza
Original Assignee
Astellas Institute For Regenerative Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47470610&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1121819(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Institute For Regenerative Medicine filed Critical Astellas Institute For Regenerative Medicine
Publication of CY1121819T1 publication Critical patent/CY1121819T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D85/00—Containers, packaging elements or packages, specially adapted for particular articles or materials
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mechanical Engineering (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
CY20191100720T 2011-11-14 2019-07-09 Φαρμακευτικα παρασκευασματα ανθρωπινων rpe κυτταρων και χρησεις αυτων CY1121819T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161559521P 2011-11-14 2011-11-14
US201261589741P 2012-01-23 2012-01-23
US201261724047P 2012-11-08 2012-11-08
PCT/US2012/065091 WO2013074681A1 (en) 2011-11-14 2012-11-14 Pharmaceutical preparations of human rpe cells and uses thereof

Publications (1)

Publication Number Publication Date
CY1121819T1 true CY1121819T1 (el) 2020-07-31

Family

ID=47470610

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100720T CY1121819T1 (el) 2011-11-14 2019-07-09 Φαρμακευτικα παρασκευασματα ανθρωπινων rpe κυτταρων και χρησεις αυτων

Country Status (23)

Country Link
US (4) US20130195806A1 (https=)
EP (2) EP2780022B2 (https=)
JP (7) JP6506023B2 (https=)
KR (1) KR102054904B1 (https=)
CN (2) CN104080464A (https=)
AU (5) AU2012340020A1 (https=)
CA (2) CA2855941A1 (https=)
CY (1) CY1121819T1 (https=)
DK (1) DK2780022T4 (https=)
ES (1) ES2734453T3 (https=)
FI (1) FI2780022T4 (https=)
GB (1) GB2496969A (https=)
HK (1) HK1202456A1 (https=)
HR (1) HRP20191110T1 (https=)
HU (1) HUE044778T2 (https=)
IL (5) IL287381B2 (https=)
LT (1) LT2780022T (https=)
PL (1) PL2780022T3 (https=)
PT (1) PT2780022T (https=)
RS (1) RS59050B1 (https=)
SI (1) SI2780022T1 (https=)
TW (5) TWI785403B (https=)
WO (1) WO2013074681A1 (https=)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2929782A1 (en) * 2004-01-23 2015-10-14 Ocata Therapeutics, Inc. Improved modalities for the treatment of degenerative diseases of the retina
US7794704B2 (en) 2004-01-23 2010-09-14 Advanced Cell Technology, Inc. Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration
DK2209888T3 (da) 2007-10-12 2020-01-20 Astellas Inst For Regenerative Medicine Forbedrede fremgangsmåder til fremstilling af rpe-celler og sammensætninger af rpe-celler
IL281453B (en) 2009-11-17 2022-07-01 Astellas Inst For Regenerative Medicine Methods for preparing human rpe cells and pharmaceutical preparations of human rpe cells
US10852069B2 (en) 2010-05-04 2020-12-01 Fractal Heatsink Technologies, LLC System and method for maintaining efficiency of a fractal heat sink
WO2012012803A2 (en) 2010-07-23 2012-01-26 Advanced Cell Technology, Inc. Methods for detection of rare subpopulations of cells and highly purified compositions of cells
ES2971646T3 (es) 2011-09-26 2024-06-06 Preanalytix Gmbh Estabilización y aislamiento de ácidos nucleicos extracelulares
US11021733B2 (en) 2011-09-26 2021-06-01 Qiagen Gmbh Stabilization and isolation of extracellular nucleic acids
ES2574956T3 (es) 2011-09-26 2016-06-23 Preanalytix Gmbh Estabilización y aislamiento de ácidos nucleicos extracelulares
IL287381B2 (en) * 2011-11-14 2024-04-01 Astellas Inst For Regenerative Medicine Pharmaceutical preparations of human rpe cells and uses thereof
CA2884915C (en) 2012-09-25 2022-05-17 Qiagen Gmbh Stabilisation of biological samples
EP2951290B1 (en) 2013-02-01 2017-11-29 The United States of America, as represented by The Secretary, Department of Health and Human Services Method for generating retinal pigment epithelium (rpe) cells from induced pluripotent stem cells (ipscs)
EP2976424B1 (en) 2013-03-18 2018-10-03 Qiagen GmbH Stabilisation of biological samples
WO2014146782A1 (en) 2013-03-18 2014-09-25 Qiagen Gmbh Stabilization and isolation of extracellular nucleic acids
WO2015080297A1 (en) 2013-11-27 2015-06-04 Kyoto Prefectural Public University Corporation Application of laminin to corneal endothelial cell culture
MX2016007671A (es) 2013-12-11 2016-10-14 Pfizer Ltd Metodo para producir celulas del epitelio pigmentario retiniano.
EP2898896A1 (en) * 2014-01-22 2015-07-29 Université Pierre et Marie Curie (Paris 6) Agents for use in the treatment of retinal inflammation
CN106102766A (zh) * 2014-01-22 2016-11-09 皮埃尔与玛丽·居里大学 - 巴黎第六大学 用于治疗视网膜炎症的试剂
CN106132200B (zh) * 2014-03-18 2020-10-30 凯杰有限公司 胞外核酸的固定和分离
WO2015175504A1 (en) * 2014-05-12 2015-11-19 The Johns Hopkins University Differentiation of human pluripotent stem cells into retinal pigment epithelium using hif1 inhibitors
US10457915B2 (en) 2014-05-15 2019-10-29 International Stem Cell Corporation Chemical differentiation of pluripotentstem cells into retinal epithelial cells
CA2949171A1 (en) 2014-05-16 2015-11-19 Koninklijke Nederlandse Akademie Van Wetenschappen Improved culture method for organoids
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
US20160095307A1 (en) 2014-10-07 2016-04-07 NuTech Medical, Inc. Method and composition for hypothermic storage of placental tissue
KR20210013299A (ko) 2014-10-17 2021-02-03 코디악 사이언시스 인코포레이티드 부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
JP6770435B2 (ja) * 2014-10-31 2020-10-14 京都府公立大学法人 ラミニンによる網膜および神経の新規治療
RU2718062C2 (ru) * 2014-10-31 2020-03-30 Сэндзю Фармасьютикал Ко., Лтд. Новое лечение роговицы с применением ламинина
KR102728629B1 (ko) * 2014-12-18 2024-11-12 쏘흐본느 유니베흐시테 망막 변성의 치료를 위한 otx2를 과발현하는 형질전환 rpe 세포
EP3240612B1 (en) * 2014-12-30 2020-12-23 Cell Cure Neurosciences Ltd. Methods of treating retinal diseases
CA2972575A1 (en) 2014-12-30 2016-07-07 Cell Cure Neurosciences Ltd. Rpe cell populations and methods of generating same
EP3916085A1 (en) 2014-12-30 2021-12-01 Cell Cure Neurosciences Ltd. Assessing retinal pigment epithelial cell populations
SG10201907918VA (en) * 2015-03-23 2019-10-30 Astellas Inst For Regenerative Medicine Improved assays for potency of human retinal pigment epithelium (rpe) cells and photoreceptor progenitors
CN105013010B (zh) * 2015-07-07 2018-01-12 中山大学中山眼科中心 一种辅助iPS‑RPE移植的层粘连蛋白膜
US11066642B2 (en) 2015-08-05 2021-07-20 Cell Cure Neurosciences Ltd Preparation of retinal pigment epithelium cells
CN108697641A (zh) 2015-08-18 2018-10-23 安斯泰来再生医药协会 临床制剂
AU2016318774B2 (en) * 2015-09-08 2022-08-18 FUJIFILM Cellular Dynamics, Inc. MACS-based purification of stem cell-derived retinal pigment epithelium
CN114457068B (zh) 2015-11-20 2025-03-14 普瑞阿那利提克斯有限公司 用于稳定细胞外核酸的已灭菌组合物的制备方法
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
GB201603569D0 (en) 2016-03-01 2016-04-13 Koninklijke Nederlandse Akademie Van Wetenschappen Improved differentiation method
CN106420809B (zh) * 2016-08-31 2017-08-08 浙江济民制药股份有限公司 一种眼科手术灌注液
WO2018111981A1 (en) * 2016-12-13 2018-06-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of preparing an isolated or purified population of thymic emigrant cells and methods of treatment using same
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
US11076984B2 (en) * 2017-03-13 2021-08-03 Gyroscope Therapeutics Limited Method of performing subretinal drainage and agent delivery
WO2018170494A1 (en) * 2017-03-16 2018-09-20 Bio Time, Inc. Methods for measuring therapeutic effects of retinal disease therapies
AU2018263853A1 (en) * 2017-05-01 2019-11-14 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods for treating ocular pathologies
GB201721615D0 (en) 2017-12-21 2018-02-07 Koninklijke Nederlandse Akademie Van Wetenschappen Immune cell organoid co-cultures
WO2019130061A2 (en) * 2017-12-29 2019-07-04 Cell Cure Neurosciences Ltd. Retinal pigment epithelium cell compositions
EP3755287B1 (en) 2018-02-22 2024-04-03 Alcon Inc. Ocular implant
EP3758737A4 (en) * 2018-03-02 2022-10-12 Kodiak Sciences Inc. IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF
SG11202104401RA (en) * 2018-11-19 2021-05-28 The United States Of America As Represented By The Secretary Biodegradable tissue replacement implant and its use
GB201819224D0 (en) 2018-11-26 2019-01-09 Koninklijke Nederlandse Akademie Van Wetenschappen Hepatocyte expansion methods
KR20220022107A (ko) * 2018-12-05 2022-02-24 아베오나 테라퓨틱스 인코퍼레이티드 유전자 전달을 위한 재조합 아데노-연관 바이러스 벡터
EP3976765A1 (en) * 2019-05-28 2022-04-06 F. Hoffmann-La Roche AG Method to generate monocytic progenitor cells
EP3886946A1 (en) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
KR102198942B1 (ko) * 2019-07-02 2021-01-05 의료법인 성광의료재단 Pedf를 발현하거나 모세포에 비하여 pedf를 과발현하도록 유전적으로 조작된 중간엽 줄기세포
WO2021034784A1 (en) 2019-08-16 2021-02-25 Poltorak Technologies, LLC Device and method for medical diagnostics
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
TW202130806A (zh) 2019-10-30 2021-08-16 安斯泰來再生醫藥協會 用於產生視網膜色素上皮細胞之方法
EP4061942A4 (en) * 2019-11-22 2023-12-20 Sigilon Therapeutics, Inc. MONOCLONAL CELL LINES EXPRESSING AN EXOGENEOUS SUBSTANCE AND THEIR USES
BR112022014246A2 (pt) 2020-01-21 2022-09-20 Takeda Pharmaceuticals Co Meio de criopreservação para criopreservar células de mamífero, kit, e, métodos de criopreservação de células de mamífero e recuperação de células viáveis
JP2023513208A (ja) * 2020-02-07 2023-03-30 ザ トラスティーズ オブ コロンビア ユニバーシティー イン ザ シティー オブ ニューヨーク 神経変性の発症を遅延させるかまたは神経変性を処置するためのメタボロームのリプログラミング
WO2022009969A1 (ja) * 2020-07-10 2022-01-13 国立研究開発法人理化学研究所 網膜色素上皮細胞の移植用生着促進剤
CN112544612A (zh) * 2020-12-18 2021-03-26 江苏艾尔康生物医药科技有限公司 冻存液及其在rpe细胞冻存中的应用
CN112834411B (zh) * 2021-01-07 2022-05-27 上海交通大学 应用于质谱流式技术的金属纳米探针及制备方法和应用
WO2022164933A2 (en) * 2021-01-26 2022-08-04 Sigilon Therapeutics, Inc. Biocompatible devices for cell-based therapies and related methods
CN112926116B (zh) * 2021-03-01 2023-02-17 哈尔滨工业大学 一种基于虚拟现实的体育馆火灾疏散行为数据收集系统及其收集方法
CN114246938A (zh) * 2022-01-25 2022-03-29 中山大学中山眼科中心 Il-4在制备用于治疗视网膜变性疾病药物中的应用
WO2023149420A1 (ja) * 2022-02-01 2023-08-10 株式会社坪田ラボ 近視を予防または治療するための方法および組成物
CN114561356B (zh) * 2022-03-09 2022-09-13 北京呈诺医学科技有限公司 影响细胞因子分泌的方法及应用
CN118871141A (zh) * 2022-03-16 2024-10-29 住友制药株式会社 移植用介质
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
EP4698206A1 (fr) * 2023-04-21 2026-02-25 PulseSight Therapeutics Compositions à base de décorine pour la réparation et la régéneration de l'épithélium pigmentaire de la rétine
EP4704870A1 (en) * 2023-05-05 2026-03-11 The Regents of University of California Retinal pigment epithelium cell therapy
CN117625536B (zh) * 2024-01-26 2024-04-30 中国人民解放军总医院第三医学中心 一种人视网膜色素上皮细胞的纯化、培养方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4138205A (en) 1975-12-15 1979-02-06 Hydro Pulse Corporation Movable stator walls permitting access to tubing in peristaltic pump
US5610753A (en) 1991-12-12 1997-03-11 Eastman Kodak Company Optical design of laser scanner to reduce thermal sensitivity
GB9608145D0 (en) * 1996-04-19 1996-06-26 British Tech Group Wound healing
US20040086494A1 (en) * 1996-10-07 2004-05-06 John Constance Mary Immune privileged cells for delivery of proteins and peptides
US5998423A (en) 1996-10-08 1999-12-07 Therasys, Inc. Methods for modulating melanin production
WO1999012572A1 (en) 1997-09-10 1999-03-18 University Of Florida Compounds and method for the prevention and treatment of diabetic retinopathy
EP1044024A1 (en) * 1998-01-02 2000-10-18 Titan Pharmaceuticals, Inc. Use of pigmented retinal epithelial cells for creation of an immune privilege site
US7410798B2 (en) 2001-01-10 2008-08-12 Geron Corporation Culture system for rapid expansion of human embryonic stem cells
US6943153B1 (en) 1999-03-15 2005-09-13 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
US6576422B1 (en) * 2000-10-17 2003-06-10 Rohm And Haas Company Method for identifying products employing gene expression
EP1339438B1 (en) 2000-11-29 2005-10-19 Allergan Inc. Preventing transplant rejection in the eye
WO2002087530A1 (en) * 2001-04-27 2002-11-07 The General Hospital Corporation Tyrosinase assay
JP2004538005A (ja) * 2001-08-08 2004-12-24 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア シアル酸に結合するタンパク質を有するウイルスベクターの精製法
MXPA04005010A (es) 2001-11-26 2005-04-08 Advanced Cell Tech Inc METODO PARA HACER Y USAR NUCLEOS CELULARES SOMáTICOS METODOS PARA HACER Y USAR NUCLEOS CELULARES SOMáTICOS HUMANOS REPROGRAMADOS Y CELULAS DEL TALLO HUMANAS AUTOLOGAS E ISOGENICAS.
US20030217374A1 (en) 2002-01-15 2003-11-20 Advanced Cell Technology Cloning B and T lymphocytes
US20040091936A1 (en) 2002-05-24 2004-05-13 Michael West Bank of stem cells for producing cells for transplantation having HLA antigens matching those of transplant recipients, and methods for making and using such a stem cell bank
US7803750B2 (en) 2002-07-29 2010-09-28 Duke University Method of modulating melanin production
EP2929782A1 (en) * 2004-01-23 2015-10-14 Ocata Therapeutics, Inc. Improved modalities for the treatment of degenerative diseases of the retina
US7794704B2 (en) * 2004-01-23 2010-09-14 Advanced Cell Technology, Inc. Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration
US7309487B2 (en) * 2004-02-09 2007-12-18 George Inana Methods and compositions for detecting and treating retinal diseases
US7893315B2 (en) 2004-11-04 2011-02-22 Advanced Cell Technology, Inc. Derivation of embryonic stem cells and embryo-derived cells
US7838727B2 (en) 2004-11-04 2010-11-23 Advanced Cell Technology, Inc. Derivation of embryonic stem cells
ZA200901914B (en) * 2006-09-22 2010-06-30 Riken Stem cell culture medium and method
DK2209888T3 (da) * 2007-10-12 2020-01-20 Astellas Inst For Regenerative Medicine Forbedrede fremgangsmåder til fremstilling af rpe-celler og sammensætninger af rpe-celler
GB0806746D0 (en) 2008-04-14 2008-05-14 Ucl Business Plc Membrane
EP2273988B1 (en) * 2008-04-18 2015-09-09 Arizona Board Of Regents, A Body Corp. Of The State Of Arizona, Acting For And On Behalf Of The University Of Arizona L-dopa for treating age-related macular degeneration
IL281453B (en) * 2009-11-17 2022-07-01 Astellas Inst For Regenerative Medicine Methods for preparing human rpe cells and pharmaceutical preparations of human rpe cells
WO2012012803A2 (en) * 2010-07-23 2012-01-26 Advanced Cell Technology, Inc. Methods for detection of rare subpopulations of cells and highly purified compositions of cells
US20110052678A1 (en) * 2010-11-05 2011-03-03 Shantha Totada R Method for treating age related macular degeneration
DK2694644T3 (en) 2011-03-30 2018-04-16 Cellular Dynamics Int Inc Priming of pluripotent stem cells for neural differentiation
ES2722207T3 (es) * 2011-04-29 2019-08-08 Univ Southern California Procedimientos para la crioconservación de células epiteliales de pigmento retiniano derivadas de citoblastos crecidas sobre un sustrato polimérico
IL287381B2 (en) * 2011-11-14 2024-04-01 Astellas Inst For Regenerative Medicine Pharmaceutical preparations of human rpe cells and uses thereof
EP3189135B1 (en) * 2014-09-05 2021-06-02 Astellas Institute for Regenerative Medicine Retinal ganglion cells and progenitors thereof

Also Published As

Publication number Publication date
JP2014533289A (ja) 2014-12-11
SI2780022T1 (sl) 2019-09-30
EP2780022B2 (en) 2022-09-07
US20150366915A1 (en) 2015-12-24
CA2855941A1 (en) 2013-05-23
TW202434266A (zh) 2024-09-01
JP6506023B2 (ja) 2019-04-24
DK2780022T3 (da) 2019-07-15
AU2019201201A1 (en) 2019-03-14
AU2021204719B2 (en) 2024-11-21
JP6899865B2 (ja) 2021-07-07
JP2025161815A (ja) 2025-10-24
TW201333200A (zh) 2013-08-16
EP2780022A1 (en) 2014-09-24
DK2780022T4 (da) 2024-09-09
JP2024037864A (ja) 2024-03-19
HUE044778T2 (hu) 2019-11-28
GB2496969A (en) 2013-05-29
RS59050B1 (sr) 2019-08-30
IL308205A (en) 2024-01-01
AU2017225146A1 (en) 2017-10-05
IL308205B2 (en) 2025-10-01
IL287381A (en) 2021-12-01
JP2018048144A (ja) 2018-03-29
WO2013074681A1 (en) 2013-05-23
TWI719277B (zh) 2021-02-21
TW202317157A (zh) 2023-05-01
CA3178098A1 (en) 2013-05-23
TW202120107A (zh) 2021-06-01
IL320536A (en) 2025-06-01
AU2021204719A1 (en) 2021-08-05
IL232600B (en) 2020-03-31
FI2780022T4 (fi) 2023-07-06
AU2012340020A1 (en) 2014-07-03
TWI842079B (zh) 2024-05-11
HRP20191110T1 (hr) 2019-09-20
AU2017225146B2 (en) 2019-01-17
US20250134932A1 (en) 2025-05-01
PT2780022T (pt) 2019-07-16
JP7404441B2 (ja) 2023-12-25
US20200405767A1 (en) 2020-12-31
JP6563996B2 (ja) 2019-08-21
PL2780022T3 (pl) 2019-11-29
AU2017225146C1 (en) 2019-08-22
CN104080464A (zh) 2014-10-01
TW201828960A (zh) 2018-08-16
GB201220511D0 (en) 2012-12-26
IL273107A (en) 2020-04-30
TWI785403B (zh) 2022-12-01
IL287381B2 (en) 2024-04-01
EP3563860A1 (en) 2019-11-06
HK1202456A1 (en) 2015-10-02
JP2022130370A (ja) 2022-09-06
EP2780022A4 (en) 2015-08-05
US20130195806A1 (en) 2013-08-01
EP2780022B1 (en) 2019-06-05
IL232600A0 (en) 2014-06-30
KR102054904B1 (ko) 2019-12-11
JP7716463B2 (ja) 2025-07-31
JP7081016B2 (ja) 2022-06-06
WO2013074681A9 (en) 2013-11-28
IL287381B1 (en) 2023-12-01
JP2019189614A (ja) 2019-10-31
IL273107B (en) 2021-12-01
IL308205B1 (en) 2025-06-01
AU2019201201B2 (en) 2021-04-08
LT2780022T (lt) 2019-07-10
AU2025201277A1 (en) 2025-03-13
TWI655286B (zh) 2019-04-01
KR20140096368A (ko) 2014-08-05
ES2734453T3 (es) 2019-12-10
JP2021113193A (ja) 2021-08-05
CN113786417A (zh) 2021-12-14

Similar Documents

Publication Publication Date Title
CY1121819T1 (el) Φαρμακευτικα παρασκευασματα ανθρωπινων rpe κυτταρων και χρησεις αυτων
MX2022003698A (es) Composiciones de nanoparticulas y metodos para inmunoterapia.
CY1126136T1 (el) Μεθοδοι θεραπειας της αρθριτιδας
AU2018338608A1 (en) Methods, compositions, and implantable elements comprising active cells
CY1119926T1 (el) Νεοι μεταλλακτες prongf και χρησεις αυτων στην παραγωγη bhta-ngf
CY1121419T1 (el) Αναστολη της φουκοσυλιωσης των πρωτεϊνων in vivo χρησιμοποιωντας αναλογα φουκοζης
CY1118105T1 (el) Αγγειογενεση χρησιμοποιωντας πλακουντιακα βλαστικα κυτταρα
MX2022003039A (es) Metodo de seleccion de donantes universales para identificar donantes de celulas nk.
EP4434550A3 (en) Human antibody drug conjugates against tissue culture
WO2016105984A3 (en) Tissue-based compositions and methods of use thereof
BR112018003822A2 (pt) material auxiliar para promover crescimento de tecido em um cólon
EP4684764A3 (en) Programmable implants
UY33890A (es) Nuevas azaindolilfenil sulfonamidas como inhibidores de serina/ treonina cinasa
ATE542553T1 (de) Dezellularisierte omentummatrix und ihre verwendung
CY1116980T1 (el) Φαρμακοτεχνικες μορφες ανταγωνιστη του vegf
CY1122771T1 (el) Φαρμακοτεχνικες μορφες παρατεταμενης αποδεσμευσης για τη χορηγηση πρωτεϊνων στον οφθαλμο και μεθοδοι για την παρασκευη αυτων
AU2017242867A8 (en) Vortioxetine pamoic acid salt and crystal form thereof
GB2492935A (en) Conjugated blood coagulation factor VIII
UA116060C2 (uk) Спосіб одержання продукту на основі глатирамеру ацетату
WO2013006671A3 (en) Compositions and methods for spinal disc repair and other surgical and non-surgical indications
EP4364741A3 (en) Polymorphic form of tg02
CY1114757T1 (el) Παραγωγα οξαζινης και η χρηση τους στη θεραπεια νευρολογικων διαταραχων
CY1115223T1 (el) Αντι-μελαγχολικο φαρμακο που παρασκευαζεται με υλικα camp απο τζιτζιφα
MX2018005226A (es) Formulaciones de anticuerpo anti-factor d.
CO2017006640A2 (es) Metodos para el desarrollo y uso de unidades de micro-agregado de funcion celular polarizada en aplicaciones de tejido usando lgr4, lgr5 y lgr 6 que expresan celulas madre epiteliales